FDA Clears Alpha Tau to Complete Pivotal Glioblastoma Trial Enrollment, Adds New Sites

summarizeSummary

Alpha Tau Medical received FDA clearance to complete enrollment for the remaining seven patients in its REGAIN recurrent glioblastoma trial and to add two new U.S. clinical sites, following positive interim safety results.

check_boxKey Events

• FDA Clears REGAIN Trial Completion

  The FDA has cleared Alpha Tau Medical to complete enrollment for the final seven patients in its U.S. REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial, following a review of the interim safety report.

• Expansion of Clinical Sites

  Two additional leading U.S. academic cancer centers have been authorized by the FDA to join the REGAIN trial, expanding geographic access and clinical expertise for the program.

• Positive Interim Safety and Efficacy Data

  The FDA's decision follows positive interim results from the first three patients, which demonstrated 100% local disease control and a 67% complete response rate, with only one associated Grade 3 serious adverse event.

• Continued Regulatory Success

  This clearance marks the latest in a series of regulatory successes, including Alpha DaRT's Breakthrough Device Designation for recurrent glioblastoma and its acceptance into the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot.

auto_awesomeAnalysis

This FDA clearance is a critical regulatory milestone for Alpha Tau Medical, allowing the company to complete enrollment in its pivotal REGAIN trial for recurrent glioblastoma. Glioblastoma is a highly aggressive cancer with very limited treatment options, making the advancement of Alpha DaRT a significant development. The decision to proceed, based on positive interim safety data and strong early efficacy signals (100% local disease control, 67% complete response rate), de-risks the trial and accelerates the path towards potential commercialization for a therapy that has already received Breakthrough Device Designation.